Drug Safety Alert – Dronedarone

Dronedarone (Multaqâ–¼) is an antiarrhythmic agent indicated in adult, clinically stable patients with history of, or current, non-permanent atrial fibrillation (AF) to prevent recurrence of AF or to lower ventricular rate. Dronedarone is available as a 400 mg film-coated tablet and the recommended dose is 400 mg twice daily. Dronederone was only approved by NICE […]